Tamiflu Treatment Guidelines for Children with Influenza

Priority Treatment Recommendations

The American Academy of Pediatrics recommends that oseltamivir treatment should be offered as early as possible for any hospitalized child clinically presumed to have influenza or with severe, complicated, or progressive illness attributable to influenza 1, 2
The American Academy of Pediatrics recommends that oseltamivir treatment should be offered to children at high risk of influenza complications regardless of illness duration 1, 3
The American Academy of Pediatrics recommends that oseltamivir treatment should be offered to children younger than 2 years, who are at increased risk of hospitalization and complications from influenza 4, 3
Oseltamivir treatment should be considered for any otherwise healthy child with influenza whose siblings are either younger than 6 months or have underlying medical conditions that predispose them to complications 1, 5
Oseltamivir treatment should be considered for any healthy child with presumed influenza when a decrease in duration of clinical symptoms is warranted 5, 6

The American Academy of Pediatrics recommends starting oseltamivir treatment as soon as possible after symptom onset, ideally within 48 hours, as earlier treatment provides better clinical outcomes 1, 2, 3
While optimal timing is within 48 hours, treatment after 48 hours of symptoms in children with moderate to severe or progressive disease has shown some benefit and should still be considered 1, 2, 4

The FDA has approved oseltamivir for children as young as 2 weeks 4, 7
The American Academy of Pediatrics supports the use of oseltamivir in both term and preterm infants from birth for treatment of influenza, as benefits likely outweigh risks 4, 3
For children under 1 year, weight-based dosing should be used 5, 3
For children 1-12 years, 2 mg/kg twice daily for 5 days (with appropriate weight-based adjustments) is recommended 1

Treatment decisions should be based on underlying conditions of the child, disease severity, time since symptom onset, and local influenza activity 1, 4
Molecular assays should be considered for diagnosis due to higher sensitivity compared to rapid antigen tests 6, 4

Timely oseltamivir treatment can reduce the duration of fever and illness symptoms and the risks of complications, including hospitalization and death 1
Standard-dose therapy is recommended, as double-dose therapy has not shown additional benefit 1
The most common side effect of oseltamivir is vomiting (15% of treated children vs. 9% receiving placebo) 1, 4
Despite some conflicting evidence regarding efficacy, major guidelines consistently recommend early treatment for high-risk children and those with severe disease 1, 3